Moderna Plans $4 Billion–$4.5 Billion Spend From 2027 Through 2030

Moderna expects cash costs of about $4 billion to $4.5 billion from 2027 through 2030, primarily driven by plans to increase oncology investment. It sees intismeran and cancer antigen therapies as foundational opportunities.